

Sanofi leverages manufacturing capacity for global supply of COVID-19 vaccine

27 April 2021 | News

Sanofi to manufacture up to 200 million doses of Moderna's vaccine in the US starting in September 2021



Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna's COVID-19 vaccine, supporting the COVID-19 pandemic and vaccine supply needs.

Sanofi will leverage its established infrastructure and manufacturing expertise at its site in Ridgefield, NJ, to perform fill and finish of up to 200 million doses of Moderna's COVID-19 vaccine, starting in September 2021.

This marks Sanofi's third commitment to provide manufacturing support. Earlier this year, Sanofi announced the company will provide support to BioNTech for 125 million doses for the European Union.

In February, Sanofi announced one of its manufacturing site in France would support Johnson & Johnson for the production of its COVID-19 vaccine at a rate of approximately 12 million doses per month. Sanofi is the only large manufacturer to support all three vaccine efforts.

Sanofi is also collaborating with GSK on a COVID-19 vaccine candidate using the same recombinant protein-based manufacturing technology as one of Sanofi's seasonal influenza vaccines, combined with GSK's established pandemic adjuvant platform.